Showing results (641-650 of 712) with videos related to

Sort By:
Pageof 72
Neuroscience|January 19, 2016
Blast exposure causes dynamic microglial/macrophage responses and microdomains of brain microvessel dysfunctionB R Huber, J S Meabon, Z S Hoffer, et al.
Science Signaling|February 25, 2016
Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosisBrian J DeBosch, Monique R Heitmeier, Allyson L Mayer, et al.
ESMO Open|June 8, 2026
Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancerE Salehi, X Chu, E L Mayer, et al.
Science (New York, N.Y.)|October 26, 2021
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variantJun Zhang, Tianshu Xiao, Yongfei Cai, et al.
Biorxiv : the Preprint Server for Biology|August 24, 2021
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variantJun Zhang, Tianshu Xiao, Yongfei Cai, et al.
NPJ Breast Cancer|August 21, 2024
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502Daniel G Stover, Roberto Salgado, Oleksander Savenkov, et al.
Archives of Environmental Contamination and Toxicology|March 18, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part I. Acute toxicity of five chemicalsF J Dwyer, F L Mayer, L C Sappington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast CancerAntonio Giordano, Priya U Kumthekar, Qingchun Jin, et al.
Clinical Breast Cancer|January 31, 2025
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical TrialsDario Trapani, Qingchun Jin, Kathy D Miller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancerE L Mayer, D Trapani, S-E Kim, et al.
Pageof 72